Angion Biomedica Corp expected to post a loss of 46  cents a share - Earnings Preview

Elicio Therapeutics

08/08/2022 12:37

* Angion Biomedica Corp  ANGN.OQ   ANGN.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 10
(estimated). 
    * The Uniondale New York-based  company is expected to
report  a
150.0% increase in revenue to $1.35 million from $540 thousand a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Angion Biomedica
Corp is
for a loss of 46 cents per share. For the same quarter last
year, the company reported a loss of 58 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Angion
Biomedica
Corp is $4.75​, above​ its last closing price of $1.09. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.37       -0.43      -0.48     Missed  -10.3
 Dec. 31 2022  -0.66       -0.62      0.58      Beat    193.9
 Sep. 30 2021  -0.72       -0.72      -0.53     Beat    26.9​
 Jun. 30 2021  -0.69       -0.69      -0.58     Beat    15.6
 ​​Mar.        -0.62       -0.62      -1.56     Missed  -150.6
 31 2021                                                
 Dec. 31 2020  -1.30       -1.30      -1.90     Missed  -46.2​
 This summary was machine generated August 8 at 11:37 GMT.  All
figures in US dollars  unless otherwise stated